收费全文 | 25877篇 |
免费 | 1784篇 |
国内免费 | 424篇 |
耳鼻咽喉 | 538篇 |
儿科学 | 408篇 |
妇产科学 | 431篇 |
基础医学 | 4182篇 |
口腔科学 | 349篇 |
临床医学 | 2009篇 |
内科学 | 5431篇 |
皮肤病学 | 983篇 |
神经病学 | 1930篇 |
特种医学 | 1747篇 |
外科学 | 3590篇 |
综合类 | 140篇 |
一般理论 | 5篇 |
预防医学 | 839篇 |
眼科学 | 665篇 |
药学 | 2270篇 |
中国医学 | 322篇 |
肿瘤学 | 2246篇 |
2023年 | 112篇 |
2022年 | 97篇 |
2021年 | 712篇 |
2020年 | 476篇 |
2019年 | 662篇 |
2018年 | 792篇 |
2017年 | 642篇 |
2016年 | 998篇 |
2015年 | 1448篇 |
2014年 | 1690篇 |
2013年 | 1755篇 |
2012年 | 2627篇 |
2011年 | 2488篇 |
2010年 | 1633篇 |
2009年 | 1323篇 |
2008年 | 1755篇 |
2007年 | 1525篇 |
2006年 | 1395篇 |
2005年 | 1237篇 |
2004年 | 1005篇 |
2003年 | 906篇 |
2002年 | 782篇 |
2001年 | 299篇 |
2000年 | 302篇 |
1999年 | 230篇 |
1998年 | 121篇 |
1997年 | 119篇 |
1996年 | 83篇 |
1995年 | 59篇 |
1994年 | 40篇 |
1993年 | 44篇 |
1992年 | 54篇 |
1991年 | 86篇 |
1990年 | 45篇 |
1989年 | 51篇 |
1988年 | 59篇 |
1987年 | 47篇 |
1986年 | 33篇 |
1985年 | 36篇 |
1984年 | 25篇 |
1983年 | 28篇 |
1980年 | 20篇 |
1979年 | 35篇 |
1978年 | 28篇 |
1977年 | 33篇 |
1976年 | 13篇 |
1975年 | 15篇 |
1974年 | 13篇 |
1973年 | 15篇 |
1971年 | 13篇 |
Introduction
The American Joint Committee on Cancer (AJCC) tumor, node, metastasis classification system (TNM) staging manual has been updated and provides more specified stage grouping for prostate cancer (PCa). We aimed to validate the updated AJCC stage groups for PCa using a radical prostatectomy (RP) cohort.Patients and Methods
We analyzed the data of 3032 patients previously treated with RP for localized PCa. We stratified patients into stage groups according to the 8th edition of the AJCC manual and compared biochemical recurrence (BCR)-free survival using Kaplan-Meier analyses.Results
There were 217 patients in stage group I, 33 in IIA, 1101 in IIB, 535 in IIC, 129 in IIIA, 781 in IIIB, and 236 in IIIC. There were no significant differences in BCR-free survival between stage groups IIC and IIIA (P = .875). Subsequently, the low–Gleason score (GS) IIIA subgroup (GS ≤ 3 + 4, P = .025) showed superior BCR-free survival than the IIC group, and the high-GS IIIA subgroups (GS ≥ 4 + 3, P = .004) showed a poorer BCR-free survival than the IIC group. Furthermore, there were no significant differences between groups I and IIA (P = 330) and between groups IIA and IIB (P = .942). Our new staging system provided a better ability to discriminate the prognosis of each group. However, our study has several limitations, such as retrospective design, relatively short follow-up period, and need for further validation.Conclusion
The current AJCC prognostic groups show some contradictory results, particularly concerning prognosis of the IIC and IIIA groups. We suggest that GS be given more weight than serum prostate-specific antigen level in stage group stratification. 相似文献Background
The purpose of the study was to compare cancer detection rates between 12-core transrectal ultrasound-guided prostate biopsy (TRUS-Bx) and multiparametric magnetic resonance imaging (mpMRI)-guided target prostate biopsy (MRI-TBx) according to prostate-specific antigen (PSA) level in biopsy-naive patients.Patients and Methods
A retrospective study was conducted in 2009 biopsy-naive patients with suspected prostate cancer (PSA ≤20 ng/mL). Patients underwent TRUS-Bx (n = 1786) or MRI-guided target prostate biopsy (MRI-TBx; n = 223) from September 2013 to March 2017 and were stratified according to each of 4 PSA cutoffs. MRI-TBx was performed on lesions with Prostate Imaging Reporting and Data System (PI-RADS) scores of 3 to 5 on mpMRI. Clinically significant prostate cancer (csPCa) was defined as Gleason ≥7. Propensity score matching was performed using the prebiopsy variables, which included age, PSA, prostate volume, and PSA density.Results
Propensity score matching resulted in 222 patients in each group. There were significant differences between the TRUS-Bx and MRI-TBx groups in the overall detection rates of prostate cancer (41.4% vs. 55.4%; P = .003) and csPCa (30.1% vs. 42.8%; P = .005). However, across PSA cutoffs, MRI-TBx detected more prostate cancer than TRUS-Bx at PSA levels of 2.5 to <4 (29.5% vs. 56.6%; P < .001). The csPCa detection rates of TRUS-Bx and MRI-TBx did not differ significantly within the PSA cutoffs. There was a significantly higher detection rate of prostate cancer and csPCa in lesions with PI-RADS scores 4 and 5 than in those with a score of 3.Conclusion
Prebiopsy mpMRI and subsequent targeted biopsy had a higher detection rate than TRUS-Bx in patients with prostate cancer and csPCa. 相似文献Method: We performed secondary data analysis on 2377 elderly individuals aged >65 years. Raw data from the Korea National Health and Nutrition Examination Survey VI (2014–2015), were drawn from a representative national sample.
Results: Of those aged ≥65 years or older, 25.4% had low handgrip strength. After adjusting for confounding variables, the odds ratios of elderly individuals with low handgrip strength were 1.30 (95% confidence interval [CI]: 1.00–1.69) for mobility, 2.18 (95% CI: 1.47–3.22) for self-care, 1.70 (95% CI: 1.30–2.23) for usual activities, 1.30 (95% CI: 1.01–1.67) for pain/discomfort, 1.03 (95% CI: 0.74–1.44) for anxiety/depression, 1.44 (95% CI: 1.10–1.87) for the EQ-5D index, and 1.37 (95% CI: 1.08–1.73) for subjective health status.
Conclusion: Health-related quality of life and subjective health status differ according to handgrip strength. Therefore, handgrip strength should be addressed to improve quality of life in elderly individuals. Elderly individuals require exercise education and adequate nutritional intake to increase handgrip strength. 相似文献